Wikidata entity: Q218842
C₁₉H₂₁N₃O (P274)
Quantities
| P4250 | defined daily dose | 10 |
| P2067 | mass | 307.168462 |
| P2101 | melting point | 196 |
| P3780 | active ingredient in | ... | Q47521025 (Ambien) | Ambien |
| P3780 | active ingredient in | ... | Q47521717 (Intermezzo) | Intermezzo |
| P3780 | active ingredient in | ... | Q47522357 (Zolpimist) | Zolpimist |
| P233 | canonical SMILES | String | CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C | ??? |
| P373 | Commons category | String | Zolpidem | ??? |
| P1343 | described by source | ... | Q316572 (Opium Law) | Opium Law |
| P527 | has part(s) | ... | Q627 (nitrogen) | nitrogen |
| P527 | has part(s) | ... | Q623 (carbon) | carbon |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P8026 | LiverTox likelihood score | ... | Q83284667 (LiverTox toxicity likelihood category E) | LiverTox toxicity likelihood category E |
| P2175 | medical condition treated | ... | Q154430 (anxiety) | anxiety |
| P2175 | medical condition treated | ... | Q1869874 (insomnia) | insomnia |
| P2175 | medical condition treated | ... | Q3184856 (substance abuse) | substance abuse |
| P2175 | medical condition treated | ... | Q177190 (sleep disorder) | sleep disorder |
| P2175 | medical condition treated | ... | Q54972453 (sleep-wake disorder) | sleep-wake disorder |
| P129 | physically interacts with | ... | Q5520260 (Gamma-aminobutyric acid type A receptor subunit alpha1) | Gamma-aminobutyric acid type A receptor subunit alpha1 |
| P129 | physically interacts with | ... | Q21113305 (Gamma-aminobutyric acid type A receptor subunit gamma2) | Gamma-aminobutyric acid type A receptor subunit gamma2 |
| P129 | physically interacts with | ... | Q21114574 (Gamma-aminobutyric acid type A receptor subunit beta1) | Gamma-aminobutyric acid type A receptor subunit beta1 |
| P129 | physically interacts with | ... | Q21114578 (Gamma-aminobutyric acid type A receptor subunit alpha3) | Gamma-aminobutyric acid type A receptor subunit alpha3 |
| P129 | physically interacts with | ... | Q21114582 (Gamma-aminobutyric acid type A receptor subunit alpha2) | Gamma-aminobutyric acid type A receptor subunit alpha2 |
| P3489 | pregnancy category | ... | Q3679234 (Australian pregnancy category B3) | Australian pregnancy category B3 |
| P3489 | pregnancy category | ... | Q28123617 (US pregnancy category C) | US pregnancy category C |
| P769 | significant drug interaction | ... | Q179996 ((RS)-methadone) | (RS)-methadone |
| P769 | significant drug interaction | ... | Q303646 (hydromorphone) | hydromorphone |
| P769 | significant drug interaction | ... | Q81225 (morphine) | morphine |
| P769 | significant drug interaction | ... | Q55434 (pethidine) | pethidine |
| P769 | significant drug interaction | ... | Q58614 (loxapine) | loxapine |
| P769 | significant drug interaction | ... | Q407592 (tramadol) | tramadol |
| P769 | significant drug interaction | ... | Q377270 (dihydrocodeine) | dihydrocodeine |
| P769 | significant drug interaction | ... | Q407535 (oxycodone) | oxycodone |
| P769 | significant drug interaction | ... | Q407541 (fentanyl) | fentanyl |
| P769 | significant drug interaction | ... | Q417915 (sufentanil) | sufentanil |
| P769 | significant drug interaction | ... | Q422244 (fluoxetine) | fluoxetine |
| P769 | significant drug interaction | ... | Q423288 (desipramine) | desipramine |
| P769 | significant drug interaction | ... | Q834280 (bupropion) | bupropion |
| P769 | significant drug interaction | ... | Q898407 (venlafaxine) | venlafaxine |
| P769 | significant drug interaction | ... | Q174723 (codeine) | codeine |
| P769 | significant drug interaction | ... | Q407617 (sertraline) | sertraline |
| P769 | significant drug interaction | ... | Q407721 (buprenorphine) | buprenorphine |
| P769 | significant drug interaction | ... | Q2622907 (periciazine) | periciazine |
| P769 | significant drug interaction | ... | Q408471 (paroxetine) | paroxetine |
| P769 | significant drug interaction | ... | Q414463 (tapentadol) | tapentadol |
| P769 | significant drug interaction | ... | Q7553347 (sodium oxybate) | sodium oxybate |
| P279 | subclass of | ... | Q47317020 (pyridine) | pyridine |
| P2868 | subject has role | ... | Q62962 (hypnotic) | hypnotic |
| P2868 | subject has role | ... | Q17164853 (GABAA receptor positive allosteric modulators) | GABAA receptor positive allosteric modulators |
| P2868 | subject has role | ... | Q50377192 (hypnotics and sedatives) | hypnotics and sedatives |
| P2868 | subject has role | ... | Q50430377 (GABA-A receptor agonist) | GABA-A receptor agonist |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | zolpidem | ??? |
Why not click here or view trends?
log id: 2710750